Zusammenfassung
Wachstum und Entwicklung der weiblichen Brustdrüse werden nomalerweise hauptsächlich durch die ovarielle Sekretion von Östrogenen und Progesteron bestimmt. Dabei sind Östrogene (vor allem Östradiol) die wichtigsten direkten Hormone für das Wachstum der 4 Gewebestrukturen der Brust (Fettgewebe, Bindegewebe, duktales und lobuläres System). Die Ausdifferenzierung der duktalen und lobulären Strukturen wird durch Gestagene (Progesteron) erreicht. Eine optimale duktal-lobuläre Morphologie setzt den ausgewogenen Synergismus von Östrogenen und Gestagenen voraus. Dabei spielen Bindungsproteine, aber auch die Reaktion des Gewebes (Rezeptorbildung undfunktion) eine Rolle. Die volle natürliche Ausreifung der Brust wird normalerweise durch die erste ausgetragene Schwangerschaft herbeigeführt.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ayers JWT, Gidwani GP (1983) The “luteal breast”: Hormonal and Sonographie investigations of benign breast disease in patients with cyclic mastalgia. Fertil Steril 40:779–784
Bässler R (1978) Pathologie der Brustdrüse. Springer, Berlin Heidelberg New York (Spezielle pathologische Anatomie Bd. 11)
Berta L, Frairia R, Brumma C, Mavello C, Mosetto C, Rovero E, Gaidano G (1983) Hormonal pattern and sex-hormone binding globulin in plasma of women with cystic breast disease. In: Angeli A, Bradlow HL, Dogliotti L (eds) Endocrinology of cystic breast disease. Raven Press, New York, pp 123–126
Brüning PF, Bonfrer JMG, Hart AAM (1985) Non protein bound estradiol, sex-hormone binding globulin, breast cancer and breast cancer risk. Br J Cancer 51:479–484
Bucher NLR, Geschickter CF (1941) Corpus luteum studies: 2. Pregnandiol and estrogen output in the urine of patients with chronic cystic mastitis. J Clin Endocrinol Metab 1:58–63
Christensen SB (1987) Correlation between non-toxic goitre and benign mastopathia. Acta Med Scand 221:395–401
Cole P, Ellwood JM, Kaplan SD (1978) Incidence rates and risk factors of benign breast neoplasm. Am J Epidemiol 108:112–116
Cuzick J, Wang DY, Bulbrook RD (1986) The prevention of breast cancer. Lancet I:83–85
Davis HH, Simons M, Davis JB (1964) Cystic disease of the breast. Relationship to cancer. Cancer 17:957–961
Drafta D, Schindler AE, Milcu STM, Keller E, Stroe E, Horodniceanu E, Balanescu I (1980) Plasma hormones in pre- and postmenopausal breast cancer patients. J Steroid Biochem 13:793–802
Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151
Enriori CL, Reforzo-Membrives J (1984) Peripheral aromatisation as a risk factor for breast and endometrial cancer in postmenopausal women: A Review. Gynecol Oncol 17:1–21
Gambrell RD (1984) Proposal to decrease the risk and to improve the prognosis of breast cancer. Am J Obstet Gynecol 150:119–132
Greenblatt RB, Chadda JS, Teran AZ, Lewis A (1984) Fibrocystic breast disease: Pathophysiology, hormonology, treatment. Contemp Surg 24:49–60
Gregl A (1983) Bei der bunten Mischung der Mastopathie empfiehlt es sich, den Köcher der hormonalen Therapie möglichst auszuschöpfen. Gynäkologe 3:16–19
Harris JR, Hellmann S, Henderson IC, Kinne DW (1987) Breast diseases. Lippincott, Philadelphia
Hirayama T, Wynder EL (1962) A study of the epidemiology of cancer of the breast II. The influence of hysterectomy. Cancer 15:28–38
Hoover R, Glass A, Finkle WD, Azevedo D, Milne K (1981) Conjugates estrogens and breast cancer risk in women. J Natl Cancer Inst 67:815 – 820
Key TJA, Pike MC (1988) The role of estrogen and progestogens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24:29–43
Kodlin D, Winger EE, Morgenstern NL, Chen V (1977) Chronic mastopathy and breast cancer. Cancer 39:2603–2607
Kumar S, Mansel RE, Hughes LE, Edwards CA, Scanlon MF (1985) Prediction of response to endocrine therapy in pronounced mastalgia using dynamic tests of prolactin release. Clin Endocrinol 23:699–704
Kvale G, Hench I (1988) Menstrual factors and breast cancer risk. Cancer 62:1625–1631
MacMahon B, Feinelib M (1960) Breast cancer in relation to nursing and menopausal history. J Natl Cancer Inst 24:733–753
MacMahon B, Trichopoulos D, Brown J, Andersen A, Cole P, De Waard F, Kouraniemi T, Polychronopoulou A, Ravnihar B, Stormly N, Westlund K (1982) Age at menarche, urine estrogens and breast cancer risk. Int J Cancer 30:427–431
Marx E, Schulz H, Maecker R (1969) Klinische Bewertung der Epithelproliferation gutartiger Mammatumoren und Mastopathien. Brun’s Beitr Klin Chir 217:220–231
Mauvais-Jarvis P, Sitruk-Ware R, Kutenn F (1982) Luteal phase insufficiency and development of breast cancer. Breast Cancer Res Treat 2:139–150
Mauvais-Jarvis P, Sitruk-Ware R, Kutenn F (1983) Luteal phase defect and benign breast disease relationship to breast cancer genesis. J Steroid Biochem 19:13
Mauvais-Jarvis P, Sitruk-Ware R, Kutenn F, Stekers N (1979) Luteal phase insufficiency: A common pathophysiologic factor in the development of benign and malignant breast diseases. Comment Res Breast Dis 1:25–29
Moore JW, Clark GMG, Bulbrook RD, Hayward JL, Murai JT, Hammond GL, Siiteri PK (1982) Serum concentration of total and non-protein-bound estradiol in patients with breast cancer and in normal controls. Int J Cancer 29:17–21
Moore JW, Clark GMG, Hoare SA, Millis RR, Hayward JL, Quinlan MA, Wang DY, Bulbrook RD (1986) Binding of estradiol to blood proteins and etiology of breast cancer. Int J Cancer 38:625–630
Moore JW, Clark GMG, Takatani O, Wakabayashi Y, Hayward JL, Bulbrook RD (1983) Distribution of 17-β-estradiol in the serum of normal British and Japanese women. J Natl Cancer Inst 71:749–754
Olsson H, Ahn P, Kristofferson U, Landing-Olsson M (1984) Hypophysial tumor and gynecomastia preceding bilateral breast cancer development in a man. Cancer 53:1974–1977
Olsson H, Landing-Olsson M, Gullberg B (1983) Retrospective assessment of menstrual cycle length in patients with breast cancer in patients with benign breast disease and in women without breast disease. J Natl Cancer Inst 70:17–20
Peters F, Geisthövel F, Breckwoldt M (1987) Treatment of benign breast disease by dopamine agonists. In: Genazzani AR, Volpe A, Facchetti F (eds) Gynecological Endocrinology. Parthenon, Lancaster, pp 275–283
Rannevik G (1987) Endocrinological aspects of benign breast disease. In: Wood C (ed) Benign breast disease: Is it worth treating? Raven Press, Oxford, pp 17–25 (Round table series Royal Society of Medicine Series No. 6)
Reed MJ, Cheng RW, Noel CT, Dudley HAF, James VHT (1983) Plasma levels of estron, estronesulfate and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res 43:3940–3943
Schindler AE, Schindler E-M (1986) Ernährung und Karzinomentstehung. In: Schindler AE (Hrsg) Prävention in Gynäkologie und Geburtshilfe. Terramed, Überlingen, S 93–100
Schindler AE, Schindler E-M (1989) Gynäkologie und Geburtshilfe in der Praxis. Hippokrates, Stuttgart
Secreto G, Recchione C, Miralgia M, Grinolso E, Cavalleri A (1984) High testosterone and low progesterone circulating levels in premenopausal patients with hyperplasia and cancer of the breast. Cancer Res 44:841–844
Sherman BM, Korenman SG (1974) Inadequate corpus luteum function: A pathophysiological interpretation of human breast cancer epidemiology. Cancer 33:1306–1309
Siiteri PK, Hammond GL, Nisker JA (1981) Increased availability of serum estrogens in breast cancer, a new hypothesis. In: Pike MC, Siiteri PK, Walsh CW (eds) Hormones and Cancer. (Banbury Report No. 8, Cold Spring Harbour Laboratories) pp 87–101
Sitruk-Ware R, Clair F, Sterkers N, Ulmann A, Mauvais-Jarvis P (1987) Prolactin secretion in benign breast diseases. Gynecol Endocrinol 1:195–200
Thomas BS (1983) Thyroid function and breast disease. In: Bulbrook RD, Taylor DJ (eds) Commentaries on Research in breast disease, vol 3. Liss, New York, pp 34–60
Trichopoulos D, Hsieh Ch, MacMahon B, Lin T, Lowe CR, Mirra AP, Ravnihar B, Sallar EJ, Valakras VG, Yuasa S (1983) Age at any birth and breast cancer risk. Int J Cancer 31:701–704
Trichopoulos D, MacMahon B, Cole P (1972) Menopause and breast cancer risk. J Natl Cancer Inst 48:605–613
Vihko R, Apter D (1984) Endocrine characteristics of adolescent menstrual cycles: Impact of early menarche. J Steroid Biochem 20:231–236
Vorherr H (1986) Fibrocystic breast disease: Pathophysiology, pathomorphology, clinical picture and management. Am J Obstet Gynecol 154:161–179
Walsh PV, McDicken IW, Bulbrook RD, Moore JW, Taylor WH, George WD (1984) Serum estradiol and prolactin concentrations during the luteal phase in women with benign breast disease. Eur J Cancer Clin Oncol 20:1345–1351
Wang DY, Fentinam IS (1985) Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat 6:5–36
Wingrave S (1982) Progestogen effects and their relationship to lipoprotein changes. In: A report on the oral contraception study of the Royal College of General Practitioners. Obstet Gynecol Scand [Suppl] 10:33–36
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag, Berlin Heidelberg New York
About this paper
Cite this paper
Schindler, A.E. (1990). Die Bedeutung der Östrogene für gutartige und bösartige Brusterkrankungen. In: Wolf, A.S., Schneider, H.P.G. (eds) Östrogene in Diagnostik und Therapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75101-1_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-75101-1_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-51745-0
Online ISBN: 978-3-642-75101-1
eBook Packages: Springer Book Archive